7-{(1R,2R,3R)-3-羟基-2-[(1E,3R)-3-羟基-4-苯氧基丁-1-烯-1-基]-5-羰基环戊基}庚-4,5-二烯酸 | 135558-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 7-{(1R,2R,3R)-3-羟基-2-[(1E,3R)-3-羟基-4-苯氧基丁-1-烯-1-基]-5-羰基环戊基}庚-4,5-二烯酸
• 英文名称: 4,5-Heptadienoic acid, 7-(3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl)-, (1R-(1alpha(R*),2beta(1E,3R*),3alpha))-
• CAS: 135558-45-1
• 化学式: C₂₂H₂₆O₆
• 分子量: 386.4
• InChiKey: BIFFPOIGTAQJKR-MBAZSWPISA-N

物化性质

• 沸点：
  615.0±55.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  恩前列素中间体 生成 7-{(1R,2R,3R)-3-羟基-2-[(1E,3R)-3-羟基-4-苯氧基丁-1-烯-1-基]-5-羰基环戊基}庚-4,5-二烯酸
  参考文献：
  名称：

  COOPER, GARY F.;WREN, L.;VAN, HORN ALBERT R.;LI, TSUNG-TEE;BENRD, COIIN C+

  摘要：

  DOI：

文献信息

• HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
  申请人：Ripple Therapeutics Corporation

  公开号：US20210347809A1

  公开（公告）日：2021-11-11

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本文描述了可加工的组合物，其中至少包含一个可在其自由形式下加工的成分。本文还描述了用于治疗眼部疾病或障碍的组合物和方法，包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞。所述组合物和方法包括表现出抗炎活性、降低眼内压力（IOP）和/或其他理想活性的类固醇和前列腺素。将所述组合物注射到眼中可为患有眼部障碍的患者提供治疗益处。
• Uses of enprostil-type prostaglandins in regulating fat and carbohydrate metabolism
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0248999A2

  公开（公告）日：1987-12-16

  This invention provides an isomer, or mixture thereof, of a compound of the formula: wherein X is hydrogen, halogen, trifluoromethyl, lower alkyl or lower alkoxy; one wavy line denotes the a configuration and the other β; or a pharmaceutically acceptable salt or lower alkyl ester thereof, and pharmaceutical compositions containing these compounds, said compounds and compositions being used for regulating fat or carbohydrate metabolism, in particular, for suppressing postprandial cholesterolemia, postprandial lipemia, postprandial chylomicronemia, postprandial serum glucose elevation, postprandial serum insulin elevation, postprandial serum GIP elevation, postprandial serum C-peptide elevation, reducing serum triglycerides, serum cholesterol or serum LDL-cholesterol, or treating atherosclerosis.

  本发明提供了一种式中化合物的异构体或其混合物： 其中 X 是氢、卤素、三氟甲基、低级烷基或低级烷氧基；一条波浪线表示 a 构型，另一条表示 β；或其药学上可接受的盐或低级烷基酯，以及含有这些化合物的药物组合物，所述化合物和组合物用于调节脂肪或碳水化合物代谢，特别是用于抑制餐后胆固醇血症、餐后脂肪血症、餐后乳糜血症、餐后血清葡萄糖升高、餐后血清胰岛素升高、餐后血清 GIP 升高、餐后血清 C 肽升高，降低血清甘油三酯、血清胆固醇或血清低密度脂蛋白胆固醇，或治疗动脉粥样硬化。
• Heterodimer compositions and methods for the treatment of ocular disorders
  申请人：Ripple Therapeutics Corporation

  公开号：US11279729B2

  公开（公告）日：2022-03-22

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

  本描述涉及一种可处理组合物，所述组合物包含至少一个以自由形式可处理的单元。此外，本描述还涉及用于治疗眼科疾病或紊乱（包括青光眼、眼睑炎、眼部炎症、糖尿病性黄斑水肿、后部炎症、前部炎症、黄斑变性（例如湿性黄斑变性（AMD）或干性AMD）、白内障手术后和视网膜静脉阻塞）的组合物和方法。所述组合物和方法包含具有抗炎活性、降低眼内压以及/或其它有益活性的类固醇和前列腺素。将所述组合物注射入眼中，为患有眼科疾病患者带来治疗益处。
• [EN] HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSITIONS HÉTÉRODIMÈRES ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021220061A2

  公开（公告）日：2021-11-04

  Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.